IVF Add-ons: The Cost of Hope When the Evidence Is Thin

IVF add-ons promise an extra chance when standard treatment feels uncertain. A 2026 review examined common adjuncts and highlighted weak or absent evidence for many of them. The useful question is not how many extras a clinic offers, but what each adds to live-birth chances, cost and risk.

“Is there anything else we can do?” is an understandable question during IVF. Add-on procedures can increase financial and emotional burden, so promised benefits deserve the same scrutiny as standard treatment.

A closer look at the review

The 2026 review in The Lancet Obstetrics, Gynaecology, & Women’s Health assessed ten common add-ons. Trial trustworthiness and evidence certainty matter; inclusion in a review does not make every trial high quality.

Specifically, the study found insufficient or low-quality evidence for the efficacy of:

Acupuncture
Corticosteroids
Endometrial Receptivity Analysis (ERA)
Intralipid infusions
Ovarian and endometrial Platelet-Rich Plasma (PRP) injections
PGT-A: Routine chromosome screening should be distinguished from PGT-M or PGT-SR for specific genetic indications.

While these procedures are frequently marketed to patients as “success boosters,” the research concludes that they have not consistently demonstrated an improvement in live birth rates.

The “Maybe” List

Some interventions did show a potential, albeit limited, benefit:

Endometrial scratching: Evidence is mixed and does not justify promising benefit to every patient.
Hyaluronic-acid transfer media: Potential benefits need interpretation in the relevant population and protocol.
PICSI: Evidence about miscarriage and live birth should be distinguished; it is not a guaranteed improvement over standard ICSI.

Ask for relevant numbers

IVF success varies substantially by age, diagnosis, embryo availability and the denominator used. A universal per-cycle percentage can obscure rather than clarify the expected benefit of an add-on.

The researchers caution that the issue is not necessarily to ban these procedures, but to ensure that patients are making evidence-based decisions. Patients are often paying thousands of dollars for treatments that have not passed the bar of rigorous clinical proof.

A better decision, not necessarily a longer invoice

Review the underlying treatment plan and the evidence for each proposed extra. More intervention is not automatically better care.

The medical consensus is shifting:

Stop searching for “miracle add-ons” and start focusing on personalized diagnostics.
Analyze the root cause: Before adding expensive procedures, ensure your medical team has thoroughly investigated individual factors like ovarian reserve, embryo quality, and uterine environment.
Choose evidence over trends: A “less is more” approach, focusing on validated protocols, is often the most realistic and cost-effective path to success.

Ultimately, the goal is not to perform more interventions, but to perform the right interventions. Hope is essential, but it must be grounded in clinical reality. For those navigating IVF, the path to a healthy baby is rarely found in the number of add-ons on an invoice, but in the precision of the care plan.

Disclaimer: This report is for informational purposes. Clinical decisions regarding supplemental IVF treatments should be made following a thorough discussion with your fertility specialist regarding the potential costs and evidence-based benefits for your specific medical history.

Read the research with its uncertainty

The authors’ briefing identifies ten add-ons and emphasizes trial quality, costs and uncertain benefits. A weak evidence base is not proof that every possible use is ineffective. Researcher briefing for The Lancet Obstetrics, Gynaecology, & Women’s Health (2026).